A Phase II Trial of Bortezomib (NSC 681239) + Lenalidomide (Revlimid, CC-5013) (NSC 703813) for Relapsed/Refractory Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 25 Feb 2013 Planned end date changed from 1 Jan 2100 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned end date changed from 1 Jun 2011 to 1 Jan 2100 as reported by ClinicalTrials.gov.
- 19 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.